Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 291 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December December 2, 2024 Cancer Research UK reports record levels of investment in its spinouts August 24, 2021 Advancing Cancer Research as a Married Couple: “Your Stories” Podcast December 18, 2020 No Link Between Caffeine Consumption and Breast Cancer, Study Finds September 29, 2021 Load more HOT NEWS Berry Recipes Five-Year Outcomes with CAR T Cell Therapy Air Pollution and Breast Cancer Risk – A Link That Calls... COVID-19 Vaccine Myth Busters
